BioMatrix is reducing post-CABG Atrial fibrillation from 40-60% to less than 5%
Our FDA-approved research is changing the standard of care for cardiac surgery worldwide.
BioMatrix's mission is to drastically reduce post-surgical AFib complications, saving time, budget, and improving patient outcomes by lowering hospital stays.
Reducing post-CABG AFib from 40-60% to less than 5%, drastically improving patient recovery.
Shorter recovery times mean reduced hospital stays, saving healthcare costs and improving patient satisfaction.
Our technology is backed by rigorous research and has received FDA approval for use in cardiac surgery.
Utilizing extracellular matrix (ECM) technology to prevent AFib after cardiac surgery
During surgery, our surgeons place or inject the extracellular matrix (ECM) or hydrogel derived from porcine placenta tissue.
The ECM signals the body to recruit stem cells to rebuild healthy tissue.
Acts as a natural scaffold for cellular growth and regrowth of injured tissue.
Prevents immune system inflammation and scar tissue formation.
BioMatrix presents a $200B market opportunity in the cardiac surgery space
Current AFib rate after CABG surgery
BioMatrix AFib rate after CABG surgery
Total addressable market size
Approved and ready for implementation
Innovative technology with global market applications and multiple revenue streams.
Low regulatory risk with existing FDA approval and proven clinical results.
Worldwide application potential with scalable manufacturing and distribution.
Strong patent portfolio protecting our proprietary ECM technology and methods.
Meet the visionaries behind BioMatrix's innovative technology
President and CEO
President and CEO, Dr. David Skinner, MD, PhD, MBA, FMHC, is a visionary physician and healthcare innovator dedicated to transforming outpatient care. While in the University of Arizona MD-PhD program, Dr. Skinner identified a significant gap between hospital care and community health, leading him to found Southern Arizona Urgent Care (SAUC) in 2012.
Chief Growth Officer
Chief Growth Officer, Melissa Mitchell brings over 21 years of business development, sales and marketing experience to the team. As the Director of Business Development at Ephibian, a global software development company, she has been building key relationships across multiple domains for the last 21 years.
Chief Science Officer
Chief Science Officer, John P. Konhilas, Ph.D. is Professor of Physiology who, over the past 30 years, built integrative and translational research projects focused on therapeutic development for cardiac health outcomes.
Interested in learning more about investment opportunities with BioMatrix? Contact us to request our investor pitch deck.
5590 E. River Road, Suite #150
Tucson, AZ 85750